Versogen, Incyte make Money Moves
It’s been an eventful month for some of Delaware’s big names. Green hydrogen startup Versogen is looking at a few million in energy department funds soon, and oncology pharma company Incyte (which is also rumored to be expanding into downtown Wilmington) recently made a new clinical dermatology acquisition. Semiconductor part manufacturer Phase Sensitive Innovations is staying in Delaware, and JPMorgan Chase opened its first location in Kent County as part of a regional expansion.
The end of software as technology
This week’s Chris Wink column is based on his keynote at the Builders Conference at Philly Tech Week 2024. It examines a changing landscape where “tech” is no longer synonymous with cloud computing, mobile apps and software development, but also applies to building things.
I think in Delaware we have been at this point, where “tech” doesn’t mean software only, for a while, though our need for software dev talent isn’t going anywhere. But maybe, just maybe, “tech” will do better addressing the potential threats of AI that it did with social media.
News Incubator: What else to know today
• Why it matters that Delaware’s healthcare boards don’t match the demographics of the state. [Spotlight Delaware]
• E15 fuel allows farmers to cut their emissions while costing less. So why is it prohibited from being sold during the summer months in Delaware? [Delaware Farm Bureau]
• The Longwood Foundation plans to turn the final Bank of America building in the Bracebridge complex into a $57 million higher education center in the heart of Wilmington. [Delaware Business Times]
• The inaugural Delaware Business Owner Summit will be held Thursday, June 20, at Hyatt Place in Dewey Beach. [Cape Gazette]
🗓️ On the Calendar
Welcome to the daily roundup of the latest from Delaware's tech and entrepreneurship scene. Want this in your inbox? Subscribe for free.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Donate to the Journalism Fund
Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.
